Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
What's the purpose of the trial?
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
The names of the study drugs involved in this study are:
* Iberdomide (a type of cereblon E3 ligase modulator)
* Elotuzumab (a type of monoclonal antibody)
* Dexamethasone (a type of steroid)
Trial status
Accepting patients
Phase
Phase 1/2
Enrollment
49
Last Updated
2 days ago
Participating Centers
There are 3 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
- Elotuzumab is a type of drug called a monoclonal antibody that is used in the treatment of multiple myeloma. Elotuzumab targets a protein called SLAMF7, which is found on multiple myeloma cells.
- Iberdomide is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.